Diary - News
All news Poxel Announces Imeglimin Phase 2b Initiation in Japan
POXEL SA, a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today provided an update on the clinical development of its two lead pipeline assets: Imeglimin, the first in a new class of oral anti-diabetic agents, and PXL770, a direct activator of the adenosine monophosphate-activated kinase (AMPK).
The first Phase 2b clinical trial site for Imeglimin has been opened in Japan, starting the planned rapid late-stage clinical development program for Imeglimin in the Japanese market.
For PXL770, preparations for the start of a Phase 1 trial in Germany are on track to obtain first clinical data by mid-2016.
